United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

22 Jul 2016
Change (% chg)

$0.03 (+0.28%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Omeros Corp announces positive data for MASP-2 Inhibitor in Experimental Model of Stroke
Thursday, 6 Nov 2014 07:00am EST 

Omeros Corp:Says positive data using derivative of OMS721 in a well-established animal model of stroke.OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2).MASP-2 is critical to function of lectin pathway, one of principal components of complement system, a key part of immune response.Omeros controls the worldwide rights to MASP-2 inhibition and to all therapeutics targeting MASP-2.Study evaluated the effect of MASP-2 blockade on neurological deficits and the size of brain infarcts 48 hours after induction of an ischemic stroke.Compared to control antibody-treated mice, mice treated with MASP-2 antibody demonstrated significantly reduced neurological deficits 48 hours after an ischemic stroke.In addition, the infarcted area of the brain was significantly smaller in MASP-2 antibody-treated mice.Similar degree of protection was also observed in gene-targeted MASP-2-deficient mice, which showed significantly lesser neurological deficits and infarct sizes compared to wild-type control mice.  Full Article

BRIEF-Omeros enters debt financing transaction for $20 mln in additional funds

* Entered into an amendment to its existing credit facility to provide company with an additional $20 million in unrestricted cash